@Article{ecn.2011.0290,
AUTHOR = {Lara Garabedian, Sofie Struyf, Ghislain Opdenakker, Silvano Sozzani, Jo Van Damme, Geneviève Laureys},
TITLE = {Langerhans cell histiocytosis: a cytokine/chemokine-mediated disorder?},
JOURNAL = {European Cytokine Network},
VOLUME = {22},
YEAR = {2011},
NUMBER = {3},
PAGES = {148--153},
URL = {http://www.techscience.com/ECN/v22n3/65818},
ISSN = {1952-4005},
ABSTRACT = {Langerhans cell histiocytosis (LCH) is a rare disorder characterized by an abnormal accumulation
and/or proliferation of cells with a Langerhans cell phenotype. Although no clear cause of LCH has been identified,
it has been postulated that LCH might be the consequence of an immune dysregulation, causing Langerhans cells to
migrate to and accumulate at various sites. Production of cytokines and chemokines is a central feature of immune
regulation. Cytokines are abundantly present within LCH lesions. We review here the potential role of cytokines and
chemokines in the pathogenesis of LCH. The type, distribution, and number of different cytokines released within
lesions can provide clues to the possible aetiology of LCH and, ultimately, might offer therapeutic possibilities using
recombinant cytokines or antagonists for this disorder.},
DOI = {10.1684/ecn.2011.0290}
}